ESMO Asia 2022 | EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancer

Avinash Khadela, PhD, L.M. College Of Pharmacy, Ahmedabad, India, explains a study comparing the EXTREME regimen to a paclitaxel-based regimen for patients with recurrent or metastatic head and neck squamous cell carcinoma. Patients were divided into two cohorts. Cohort 1 received the EXTREME regimen of cetuximab, cisplatin, and 5-fluorouracil (5-FU) while Cohort 2 received cetuximab, cisplatin, and paclitaxel. Dr Khadela discusses the rationale behind replacing 5-FU with paclitaxel and talks on previous studies in which 5-FU has been replaced by docetaxel. In this study, the paclitaxel-based regimen was found to lead to no improvement in overall survival but did result in a significant improvement in progression-free survival. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.